Search

Displaying results 3181 - 3190 of 8469 in total
  1. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010. … Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.

  2. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. … TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level[A228793].

  3. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115] … It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone.

  4. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  5. Drug

    Diazepinomicin

    go.drugbank.com/drugs/DB12420
    Investigational

    Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. … Discovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and

  6. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    ZFPs are involved in viral replication and packaging as well as normal cell homeostatic functions. … Picolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses.

  7. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

  8. Drug

    Mitoxantrone

    go.drugbank.com/drugs/DB01204
    ApprovedInvestigational

    An anthracenedione-derived antineoplastic agent.

  9. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI).

  10. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    as the endogenously available form. … Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.